MAP1LC3A and cancer: The first study on LC3 expression in gastrointestinal cancers (esophageal, gastric, and colorectal) employing immunohistochemistry was performed by Yoshioka et al., who showed that, in all examined cancer types, LC3 expression was significantly elevated in comparison to normal adjacent tissue.